Evaxion A (EVAX) EBIT Margin (2024 - 2025)
Evaxion A (EVAX) reported EBIT Margin of 40.34% for Q3 2025, up 9771.0% on a YoY basis from 0.41% in Q3 2024, and up 343981.4% quarter-over-quarter from 0.01% in Q2 2025.
Evaxion A (EVAX) EBIT Margin (2024 - 2025) Analysis & Trends
Evaxion A has reported EBIT Margin for 2 years, with the latest figure at 40.34% in Q3 2025.
- For the quarter ending Q3 2025, EBIT Margin rose 9771.0% year-over-year to 40.34%; the trailing twelve-month figure through Mar 2026 stood at 0.02% (up 43131.0% YoY), and the FY2025 full-year result was 122.66%, up 31789.0% from the prior year.
- EBIT Margin for Q3 2025 stood at 40.34%, up from 0.01% in the prior quarter.
- The five-year high for EBIT Margin was 40.34% in Q3 2025, with the low at 8619.61% in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 17.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 40.34% |
| Jun 30, 2025 | -0.01% |
| Dec 31, 2024 | -3,298.36% |
| Sep 30, 2024 | -57.37% |
| Jun 30, 2024 | -2,974.68% |
| Mar 31, 2024 | -8,619.61% |